NCT05556967View on ClinicalTrials.gov

Identification of Surrogate Blood and/or Urine Biomarker for Immulina TM (Trademark) in Normal Humans

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 9, 2023

Primary Completion Date

October 19, 2023

Study Completion Date

October 19, 2023

Conditions
Adherence, Patient
Interventions
DRUG

Immulina

Immulina is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.

Trial Locations (1)

39216

Clinical Research and Trials Unit - University of Mississippi Medical Center, Jackson

All Listed Sponsors
collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

lead

University of Mississippi Medical Center

OTHER